目的 探討摩羅丹聯(lián)合鋁碳酸鎂治療慢性萎縮性胃炎的臨床療效。方法 選取2019年1月—2020年12月北京京煤集團(tuán)總醫(yī)院消化科門(mén)診就診的128例慢性萎縮性胃炎患者，按隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各64例。對(duì)照組口服鋁碳酸鎂片，1片/次，3次/d，餐后1～2 h服用。治療組在對(duì)照組基礎(chǔ)上口服摩羅丹，16丸/次，3次/d，飯前用溫開(kāi)水送服。兩組療程均為3個(gè)月。觀察兩組的臨床療效，比較治療前后兩組癥狀積分、慢性病患者生命質(zhì)量測(cè)定量表體系之慢性胃炎量表（QLICD-CG）評(píng)分及血清胃泌素-17（G-17）、胃蛋白酶原Ⅰ（PGⅠ）水平和PGⅠ與PGⅡ比值（PGR）。并比較治療前和1年胃鏡隨訪時(shí)兩組胃固有腺體萎縮程度。結(jié)果 治療后，治療組總有效率是93.75%，較對(duì)照組81.25%顯著提高（P＜0.05）。治療后，兩組主、次癥積分及其總積分均顯著降低（P＜0.05），而QLICD-CG評(píng)分均顯著升高（P＜0.05）；且治療后，治療組癥狀積分和QLICD-CG評(píng)分改善優(yōu)于對(duì)照組（P＜0.05）。治療后，兩組血清G-17、PGⅠ水平和PGR均顯著升高（P＜0.05）；且治療后，治療組G-17、PGⅠ水平和PGR均顯著高于對(duì)照組（P＜0.05）。1年隨訪時(shí)，兩組胃固有腺體萎縮程度均顯著減輕（P＜0.05）；且1年隨訪時(shí)，治療組胃固有腺體萎縮程度顯著優(yōu)于對(duì)照組（P＜0.05）。結(jié)論 摩羅丹聯(lián)合鋁碳酸鎂對(duì)慢性萎縮性胃炎患者有確切療效，能有效促進(jìn)患者臨床癥狀消減，改善胃黏膜萎縮程度及功能狀態(tài)，使患者生命質(zhì)量得到提高，安全性良好。

Objective To explore the clinical efficacy of Moluodan combined with hydrotalcite in treatment of chronic atrophic gastritis. Methods A total of 128 patients with chronic atrophic gastritis admitted to the Gastroenterology Department of Beijing Jingmei Group General Hospital from January 2019 to December 2020 were selected and divided into control group and treatment group according to random number table method, with 64 cases in each group. Patients in the control group were po administered with Hydrotalcite Tablets1 to 2 hours after meal, 1 tablet/time, 3 times daily. Patients in the treatment group were po administered with Moluodan on the basis of the control group with warm water before meals, 16 pills/time, 3 times daily. The treatment course of both groups was 3 months. The clinical efficacy of the two groups was observed. The symptom scores, chronic gastritis scale (QLICD-CG) score of chronic disease patients' quality of life measurement scale system, serum gastrin-17 (G-17), pepsinogen I (PG I) and the ratio of PG I to PG II (PGR) were compared between the two groups before and after treatment. The atrophy of gastric intrinsic glands was compared between the two groups before treatment and at 1 year gastroscopic follow-up. Results After treatment, the total effective rate of the treatment group was 93.75%, which was significantly higher than that of the control group 81.25% (P < 0.05). After treatment, the scores of primary and secondary symptoms and their total scores were significantly decreased (P < 0.05), but the QLICD-CG scores were significantly increased (P < 0.05). After treatment, symptom score and QLICD-CG score in the treatment group were better than those in the control group (P < 0.05). After treatment, serum G-17, PG Ⅰ levels and PGR in two groups were significantly increased (P < 0.05). After treatment, the levels of G-17, PG Ⅰ and PGR in treatment group were significantly higher than those in control group (P < 0.05). At 1-year follow-up, the atrophy degree of gastric inherent glands was significantly reduced in both groups (P < 0.05). At 1-year follow-up, the atrophy degree of gastric inherent glands in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion Moluodan combined with hydrotalcite has definite curative effect in treatment of chronic atrophic gastritis, and can effectively promote the reduction of clinical symptoms, improve the degree of gastric mucosa atrophy and functional status, which can improve the life quality of patients with good safety.

R975

北京京煤集團(tuán)總醫(yī)院院級(jí)科研基金項(xiàng)目（ZZ2023-24）